Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Liver Failure Clinical Trials

A listing of Liver Failure medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (6) clinical trials

RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure

Granulocyte colony-stimulating factor (G-CSF) can be used to mobilize stem cells to the periphery and the liver tissue in patients with advanced liver disease, and could promote hepatic regeneration. Moreover, G-CSF was reported to protect patients from sepsis by restoring the function of both neutrophils and monocytes. Therefore, G-CSF therapy ...

Phase

Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy

To evaluate whether albumin administration after an episode of hepatic encephalopathy ( grade II) improves survival at 30, 90 and 180 days. to evaluate the effects of albumin on hepatic encephalopathy recurrence during the study period. To analyze whether albumin administration reduces hospitalization requirement. To study the effects of albumin ...

Phase

Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography

Since early times coagulopathy is considered to be an integral part of liver failure. Whether it is acute liver failure (ALF) or acute on chronic liver failure (ACLF), patients usually have deranged coagulation parameters (platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR). Based ...

Phase

Rifaximin Versus Lactulose in Renal Failure

The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, ...

Phase

Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation

Acute kidney injury (AKI) following liver transplantation (LT) has shown a wide range of between 17% and 95% and is associated with increased costs, morbidity, and mortality. The etiology of AKI after LT is multifactorial. Among these factors, renal ischemia-reperfusion injury (IRI) caused by perioperative renal hypoperfusion is considered as ...

Phase

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

Patients will be selected based on diminished likelihood of receiving a liver from the waitlist within a period during which they would be likely to succumb to severe comorbidities. This will be determined in part through use of a patient's MELD score, listing status, and clinical judgment. To ensure maximal ...

Phase